The metabolomics of asthma control: a promising link between genetics and disease
Authors:
Open Access
- 7 May 2015
- journal article
- research article
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 3 (3) , 224-238
Abstract
Short‐acting β agonists (e.g., albuterol) are the most commonly used medications for asthma, a disease that affects over 300 million people in the world. Metabolomic profiling of asthmatics taking β agonists presents a new and promising resource for identifying the molecular determinants of asthma control. The objective is to identify novel genetic and biochemical predictors of asthma control using an integrative “omics” approach. We generated lipidomic data by liquid chromatography tandem mass spectrometry (LC‐MS), using plasma samples from 20 individuals with asthma. The outcome of interest was a binary indicator of asthma control defined by the use of albuterol inhalers in the preceding week. We integrated metabolomic data with genome‐wide genotype, gene expression, and methylation data of this cohort to identify genomic and molecular indicators of asthma control. A Conditional Gaussian Bayesian Network (CGBN) was generated using the strongest predictors from each of these analyses. Integrative and metabolic pathway over‐representation analyses (ORA) identified enrichment of known biological pathways within the strongest molecular determinants. Of the 64 metabolites measured, 32 had known identities. The CGBN model based on four SNPs (rs9522789, rs7147228, rs2701423, rs759582) and two metabolites—monoHETE_0863 and sphingosine‐1‐phosphate (S1P) could predict asthma control with an AUC of 95%. Integrative ORA identified 17 significantly enriched pathways related to cellular immune response, interferon signaling, and cytokine‐related signaling, for which arachidonic acid, PGE2 and S1P, in addition to six genes (CHN1, PRKCE, GNA12, OASL, OAS1, and IFIT3) appeared to drive the pathway results. Of these predictors, S1P, GNA12, and PRKCE were enriched in the results from integrative and metabolic ORAs. Through an integrative analysis of metabolomic, genomic, and methylation data from a small cohort of asthmatics, we implicate altered metabolic pathways, related to sphingolipid metabolism, in asthma control. These results provide insight into the pathophysiology of asthma control.Keywords
This publication has 55 references indexed in Scilit:
- Predicting asthma exacerbations in childrenCurrent Opinion in Pulmonary Medicine, 2012
- Genomewide Association betweenGLCCI1and Response to Glucocorticoid Therapy in AsthmaNew England Journal of Medicine, 2011
- Metabolite profiles and the risk of developing diabetesNature Medicine, 2011
- Association between ORMDL3, IL1RL1 and a deletion on chromosome 17q21 with asthma risk in AustraliaEuropean Journal of Human Genetics, 2010
- A Large-Scale, Consortium-Based Genomewide Association Study of AsthmaNew England Journal of Medicine, 2010
- The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene functionNucleic Acids Research, 2010
- Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblastsNature Genetics, 2009
- The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shoresNature Genetics, 2009
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesThe American Journal of Human Genetics, 2007
- Guideline-defining asthma clinical trials of the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research and Education NetworkJournal of Allergy and Clinical Immunology, 2007